Protective efficacy of conjugate vaccines against experimental challenge with porcine Actinobacillus pleuropneumoniae

Byrd, Wyatt; Harmon, B. G.; Kadis, Solomon

doi:10.1016/0165-2427(92)90172-m

Cited by 25 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although some conjugates have previously been suggested for veterinary medicine use (25)(26)(27)53), so far none have been marketed. For the first time, we report the feasibility of a glycoconjugate vaccine to protect pigs from S. suis type 2 infections.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine

et al. 2016

View full text Add to dashboard Cite

dStreptococcus suis serotype 2 is an encapsulated bacterium and one of the most important bacterial pathogens in the porcine industry. Despite decades of research for an efficient vaccine, none is currently available. Based on the success achieved with other encapsulated pathogens, a glycoconjugate vaccine strategy was selected to elicit opsonizing anti-capsular polysaccharide (anti-CPS) IgG antibodies. In this work, glycoconjugate prototypes were prepared by coupling S. suis type 2 CPS to tetanus toxoid, and the immunological features of the postconjugation preparations were evaluated in vivo. In mice, experiments evaluating three different adjuvants showed that CpG oligodeoxyribonucleotide (ODN) induces very low levels of anti-CPS IgM antibodies, while the emulsifying adjuvants Stimune and TiterMax Gold both induced high levels of IgGs and IgM. Dose-response trials comparing free CPS with the conjugate vaccine showed that free CPS is nonimmunogenic independently of the dose used, while 25 g of the conjugate preparation was optimal in inducing high levels of anti-CPS IgGs postboost. With an opsonophagocytosis assay using murine whole blood, sera from immunized mice showed functional activity. Finally, the conjugate vaccine showed immunogenicity and induced protection in a swine challenge model. When conjugated and administered with emulsifying adjuvants, S. suis type 2 CPS is able to induce potent IgM and isotype-switched IgGs in mice and pigs, yielding functional activity in vitro and protection against a lethal challenge in vivo, all features of a T cell-dependent response. This study represents a proof of concept for the potential of glycoconjugate vaccines in veterinary medicine applications against invasive bacterial infections.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Despite the popular use of glycoconjugate vaccines in human medicine, this strategy has been poorly developed for veterinary practice. A CPS conjugate vaccine has been suggested for veterinary use against Actinobacillus pleuropneumoniae, the etiological agent of porcine pleuropneumonia (25)(26)(27).…”

mentioning

confidence: 99%

Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine

et al. 2016

View full text Add to dashboard Cite

show abstract

“…It is used against many endoparasites in a wide range of hosts. Toxicology studies in companion animals support a wide margin of safety for OBZ (2,3). Attempts to determine an LD50 for OBZ in small laboratory…”

Section: Introductionmentioning

confidence: 99%

Effects of endobronchial challenge with actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with inactivated vaccines containing the APX toxins

Chiers

Overbeke

Laender

et al. 1998

Veterinary Quarterly

View full text Add to dashboard Cite

“…These vaccines are partially successful in reducing the mortality but are ineffective in preventing chronic lung lesions [1,6,10]. Recently, there are many reports about pathogenic factors and protective factors against A. pleuropneumoniae infection.…”

mentioning

confidence: 99%

“…In 1986, a vaccine composed of whole cell bacteria of A. pleuropneumoniae serotype 2 was introduced to the Japanese market. The vaccine was effective in decreasing the mortality rate, but did not prevent infections [1,6,10]. Therefore, the protective effect of the vaccine was considered to be inadequate.…”

mentioning

confidence: 99%

A Field Trial of Oil Adjuvanten Trivalent Actinobacillus pleuropneumoniae Vaccine.

Oishi

Kitajima

Nakamura

et al. 1997

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. The trivalent vaccine of A. pleuropneumoniae serotype 1, 2 and 5 (AP3V) was prepared in the oil-in-water type adjuvanten form. At an SPF farm, the vaccinated pigs were observed for their antibody response, finishing rate, and lung lesions at the time of slaughter and for injection scars. The CF titers against serotype 1, 2 and 5 started to rise after the second injection, showed the highest titer at 30 days after injection and then gradually decreased in vaccinated pigs. The finishing rate in the vaccinated group was 91.6% and that in the control group immunized with commercial vaccine was 60%. The lungs in the control pigs showed severe pneumonia with hyperemia, pleural adhesion and abscess. In contrast, vaccinated pigs showed slight pneumonia. Injection scars were not observed in vaccinated pigs 100 days after the second injection. In conclusion, the pigs immunized with AP3V were sufficiently protected against A. pleuropneumoniae infection and the trial proved to be satisfactory in the safety of the vaccine under field conditions. -KEY WORDS : Actinobacillus pleuropneumoniae, field trial, vaccine.

show abstract

Protective efficacy of conjugate vaccines against experimental challenge with porcine Actinobacillus pleuropneumoniae

Cited by 25 publications

References 21 publications

Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine

Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine

Effects of endobronchial challenge with actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with inactivated vaccines containing the APX toxins

A Field Trial of Oil Adjuvanten Trivalent Actinobacillus pleuropneumoniae Vaccine.

Contact Info

Product

Resources

About